ArticleClinical and translational allergy2026
Real-World Effectiveness and Safety of Triple-Mite SCIT With Dermatophagoides and Blomia tropicalis.
Article in Clinical and translational allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundHouse dust mite (HDM)-induced respiratory allergy is a major global health problem. Species distribution varies by region and climate; Blomia tropicalis is prevalent in tropical and subtropical areas and often coexists with Dermatophagoides spp. Although allergen immunotherapy (AIT) reduces symptoms and medication use, real-world evidence for formulations including B. tropicalis remains limited.
objectivesTo evaluate the real-world effectiveness and safety of triple-mite subcutaneous immunotherapy (SCIT) with glutaraldehyde-polymerized extracts of Dermatophagoides pteronyssinus, Dermatophagoides farinae, and B. tropicalis.
methodsClinical records of 208 patients (5-65 years) with mite-induced allergic rhinoconjunctivitis, with or without asthma, sensitized to these mites were analyzed. All received ≥ 12 months of SCIT. Follow-up extended up to 5 years. Effectiveness was assessed annually using mixed models for repeated measures based on combined symptom and medication scores for rhinoconjunctivitis (RCSMS) and asthma (ACSMS), and individual symptom and medication scores. Safety was evaluated by recording adverse reactions.
resultsSignificant and sustained improvements were observed. Adjusted LS-mean RCSMS decreased from 3.97 at baseline to 2.26 at 1 year and 1.24 at 5 years (-43.1% and -68.8%; p < 0.001). ACSMS decreased from 2.74 to 1.36 and 0.46 (-50.5% and -83.3%). Symptom improvement was early and accompanied by progressive reductions in medication use. Safety was favourable, with one mild grade 1 systemic reaction (0.48% of patients; 0.015% per injection), resolving without treatment modification.
conclusionsTriple-mite SCIT was associated with sustained, clinically meaningful reductions in symptoms and medication use, and showed a favourable safety profile, supporting a favourable benefit-risk balance in regions where these mites coexist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.